Coherus BioSciences Management to Present at the 38th Annual J.P. Morgan Healthcare ConferenceHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Coherus BioSciences Management to Present at the 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireJanuary 3, 2020ReblogShareTweetShareREDWOOD CITY, Calif., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 11:00 a.m. PT, being held in San Francisco.The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.About Coherus BioSciences, Inc.Coherus is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus commercializes UDENYCA® (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA® in the European Union. Coherus is advancing a late-stage clinical product CHS-1420 (adalimumab biosimilar) and Bioeq’s Lucentis® (ranibizumab biosimilar) towards commercialization, and early-stage clinical products, CHS-2020, an Eylea® (aflibercept biosimilar), and CHS-131, a small molecule for nonalcoholic steatohepatitis (NASH) and multiple sclerosis. For additional information, please visit www.coherus.com.ContactDavid S. ArringtonVP, Investor Relations & Corporate AffairsCoherus BioSciences, Inc.darrington@coherus.com+1 (650) 395-0196ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo Finance'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo FinanceWhat to watch in the markets: Friday, February 28Yahoo Finance VideoCoronavirus just sent the Dow crashing 1,100 points and it could get worseYahoo Finance